taletrectinib
baoyuan biopharma,anheart therapeutics,innovent biologics
['taletrectinib', 'innovent bio', 'anheart', 'innovent biologics']
anheart therapeutics and innovent biologics present updated phase 2 efficacy and safety data of taletrectinib (ros1 inhibitor) at asco 2022 #pharmanews #clinicalresearchnews #biotechnews #lifesciencesnews #medicalnews #healthcarenews #pharmiwebnews 
News from across the pharmaceutical and biotech industry from PharmiWeb https://t.co/ea1b58MZYg